influenza vaccine
- Generic Name
- influenza vaccine
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
- Conditions
- Influenza VaccineImmunocompromised Patients
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 147
- Registration Number
- NCT06738082
- Locations
- 🇨🇭
Universitsy Hospital Bern, Bern, Switzerland
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
- Conditions
- InfluenzaSARS-CoV-2
- Interventions
- Biological: mRNA-1083 Composition 1 Dose A Lot ABiological: mRNA-1083 Composition 1 Dose A Lot BBiological: mRNA-1083 Composition 1 Dose BBiological: mRNA-1083 Composition 1 Dose CBiological: mRNA-1083 Composition 2 Dose ABiological: mRNA-1083 Composition 2 Dose BBiological: mRNA-1083 Composition 3 Dose ABiological: mRNA-1083 Composition 3 Dose BBiological: Investigational Influenza VaccineBiological: Investigational COVID-19 Vaccine Lot ABiological: Investigational COVID-19 Vaccine Lot B
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT06864143
- Locations
- 🇺🇸
Headlands Research Scottsdale, Scottsdale, Arizona, United States
🇺🇸Artemis Research (Headlands), San Diego, California, United States
🇺🇸Clinical Research Atlanta (Headlands), Stockbridge, Georgia, United States
Maternal Determinants of Immunity to Influenza
- Conditions
- Maternal-Fetal RelationsInfluenzaImmunoglobulinsVaccination; Infection
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Centre Hospitalier Universitaire Saint Pierre
- Target Recruit Count
- 109
- Registration Number
- NCT06716567
- Locations
- 🇧🇪
CHU Saint-Pierre, Brussels, Belgium
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
- Conditions
- COVID-19 ImmunizationInfluenza Immunization
- Interventions
- Biological: IIV-HD + rC19 (dose 3)Biological: IIV-HD + rC19 (dose 4)Biological: rC19 (dose 1)Biological: IIV-HD + rC19 (dose 1)Biological: IIV-HD + rC19 (dose 2)Other: Placebo (0.9% NaCl)
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 980
- Registration Number
- NCT06695117
- Locations
- 🇺🇸
Synexus New York Site Number : 8400007, New York, New York, United States
🇺🇸Simon Williamson Clinic - Birmingham- Site Number : 8400003, Birmingham, Alabama, United States
🇺🇸Synexus Clinical Research- Site Number : 8400004, Chicago, Illinois, United States
Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults
- Conditions
- COVID-19
- Interventions
- Biological: Influenza vaccine, adjuvantedOther: Placebo
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 1499
- Registration Number
- NCT06279871
- Locations
- 🇦🇺
Paratus Clinical Central Coast, Central Coast, New South Wales, Australia
🇦🇺Australian Clinical Research Network (ACRN), Sydney, New South Wales, Australia
🇦🇺Emeritus Research Sydney, Sydney, New South Wales, Australia
HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Federico Martinón Torres
- Target Recruit Count
- 114011
- Registration Number
- NCT06141655
- Locations
- 🇪🇸
General Public Health Directorate of Galician Health Service, Santiago de Compostela, A Coruña, Spain
Agaricus Bisporus and Influenza Vaccination Response
- Conditions
- Immune Response
- Interventions
- Dietary Supplement: Agaricus bisporus capsulesDietary Supplement: Control capsules
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 88
- Registration Number
- NCT06041867
- Locations
- 🇳🇱
Maastricht University Medical Center, Maastricht, Limburg, Netherlands
Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05909423
- Locations
- 🇩🇰
Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Zealand, Denmark
Body and Social Behavior
- Conditions
- Psychology, SocialInflammationDefeat, SocialInteraction, Social
- Interventions
- Biological: Placebo
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 104
- Registration Number
- NCT05654441
- Locations
- 🇺🇸
Clinical and Translation Research Center, Chapel Hill, North Carolina, United States
🇺🇸Howell Hall, Chapel Hill, North Carolina, United States
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
- Conditions
- InfluenzaCOVID-19
- Interventions
- Drug: CIC Vaccine with Matrix-M AdjuvantDrug: qNIV Vaccine with Matrix-M AdjuvantDrug: SARS-CoV-2 rS Vaccine with Matrix-M AdjuvantOther: Placebo Comparator
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Novavax
- Target Recruit Count
- 1579
- Registration Number
- NCT05519839
- Locations
- 🇦🇺
Oztrials Clinical Research, Drummoyne, New South Wales, Australia
🇦🇺East Sydney Doctors, Darlinghurst, New South Wales, Australia
🇦🇺Menzies Darwin, Tiwi, Norther Territory, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.